Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Volumn 22, Issue 8, 2016, Pages 1937-1944

  Bessissow, Talat ^a   Le, Ngoc Han ^a   Rollet, Kathleen ^b   Afif, Waqqas ^a   Bitton, Alain ^a   Sebastiani, Giada ^a,b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

disease activity; inflammatory bowel disease; liver fibrosis; non alcoholic fatty liver disease; non invasive methods

Indexed keywords

ALCOHOL; AZATHIOPRINE; BIOLOGICAL MARKER; MESALAZINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ASSESSMENT OF HUMANS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; HARVEY BRADSHAW INDEX; HAZARD RATIO; HEPATIC STEATOSIS INDEX; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MAYO SCORE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATIENT HISTORY OF SURGERY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SERUM; STEROID THERAPY; ULCERATIVE COLITIS; BLOOD; BODY MASS; DIABETES MELLITUS; MIDDLE AGED; PATHOLOGY; PLATELET COUNT; QUEBEC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX FACTOR;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; BODY MASS INDEX; DIABETES MELLITUS; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLATELET COUNT; PROPORTIONAL HAZARDS MODELS; QUEBEC; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84979955404     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000832     Document Type: Article

References (48)

1. Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26: 811-817
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-1429
3. Cappello M, Randazzo C, Bravata I, et al. Liver function test abnormalities in patients with inflammatory bowel diseases: a Hospital-based survey. Clin Med Insights Gastroenterol. 2014;7:25-31
4. Roman AL, Munoz F. Comorbidity in inflammatory bowel disease. World J Gastroenterol. 2011;17:2723-2733
5. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367-372
6. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-1850
7. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131
8. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatology. 2010;53:372-384
9. Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis. 2012;25:10-16
10. Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol. 2012;26: 353-357
11. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419
12. Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 2012;19 (suppl 1):18-32
13. Bringiotti R, Ierardi E, Lovero R, et al. Intestinal microbiota: the explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol. 2014;5:550-559
14. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887
15. Gisbert JP, Luna M, Gonzalez-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106-1114
16. Sourianarayanane A, Garg G, Smith TH, et al. Risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:e279-e285
17. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417-420
18. Gizard E, Ford AC, Bronowicki JP, et al. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:3-15
19. Barbero-Villares A, Mendoza Jimenez-Ridruejo J, Taxonera C, et al. Evaluation of liver fibrosis by transient elastography (Fibroscan(R)) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol. 2012;47:575-579
20. Thin LW, Lawrance IC, Spilsbury K, et al. Detection of liver injury in IBD using transient elastography. J Crohns Colitis. 2014;8:671-677
21. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017-1044
22. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42: 503-508
23. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082-1090
24. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104-1112
25. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-2023
26. Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24: 248-254
27. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-36
28. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7392-7402
29. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753
30. WHO. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva, Switzerland: World Health Organization; 2000
31. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology. 2007;46:1387-1391
32. Whalley S, Puvanachandra P, Desai A, et al. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med. 2007;7:119-124
33. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005; 41:64-71
34. Sebastiani G, Rollet-Kurhajec KC, Pexos C, et al. Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis. 2015;2:ofv015
35. Kahl S, Strassburger K, Nowotny B, et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One. 2014;9:e94059
36. Sebastiani G, Castera L, Halfon P, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of noninvasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 2011;34:1202-1216
37. Hasson H, Merli M, Galli L, et al. Non-invasive fibrosis biomarkers-APRI and Forns-are associated with liver stiffness in HIVmonoinfected patients receiving antiretroviral drugs. Liver Int. 2013; 33:1113-1120
38. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854
39. Verma S, Jensen D, Hart J, et al. Predictive value of ALT levels for nonalcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33:1398-1405
40. Fukuda K, Fujita Y. Determination of the discriminant score of intestinal microbiota as a biomarker of disease activity in patients with ulcerative colitis. BMC Gastroenterol. 2014;14:49
41. Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: so far, so near. World J Hepatol. 2015;7:315-326
42. Rojas-Feria M, Castro M, Suarez E, et al. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19:7327-7340
43. Alcorn N, Tierney A, Wu O, et al. Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheumatic Dis. 2010;69:1571
44. McGowan CE, Jones P, Long MD, Barritt AS. Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-A case series and review of the literature. Inflamm Bowel Dis. 2012;18:49-54
45. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41: 175-179
46. Macias J, Gonzalez J, Tural C, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS. 2014;28: 1279-1287
47. Sebastiani G, Ghali P, Wong P, et al. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. Can J Gastroenterol Hepatol. 2014;28:23-30
48. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50:1072-1078